B. Braun SE
B. Braun SE is a privately held German medical technology and pharmaceutical company that manufactures infusion therapy systems, surgical instruments, dialysis products, and clinical nutrition solutions for hospitals and home healthcare patients across more than 40 countries. Revenue reached €9.4 billion in FY2025.
- Company typePrivate
- Founded1839
- HeadquartersMelsungen, Germany
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What B. Braun SE does
B. Braun SE is a privately held German medical technology and pharmaceutical company headquartered in Melsungen, founded in 1839 and structured as a Societas Europaea under family ownership with Anna Maria Braun as Chair of the Management Board. The company manufactures and sells medical devices, sterile pharmaceutical products, and integrated care solutions spanning more than 15 therapy areas including infusion therapy, surgical instruments and visualization, clinical nutrition, extracorporeal blood treatment (dialysis), interventional vascular therapy, minimally invasive and robotic surgery, wound management, orthopedic joint replacement, pain therapy, continence care and urology, neurosurgery, spinal surgery, and hygiene management. Notable proprietary products include the Spaceplus automated infusion system with the OnlineSuite digital medication management platform, the AESCULAP EinsteinVision 3.0 FI 3D fluorescence imaging system, and a coin-sized implantable intracranial pressure sensor approved by Australia's TGA for hydrocephalus management. The company operates through wholly-owned subsidiaries including B. Braun Melsungen AG (infusion and IV equipment), Aesculap (surgical instruments), B. Braun Renal Care (dialysis centers), and the rebranded B. Braun Pharma & MedTech Partner (OEM and contract development services), serving customers across more than 40 countries with a direct enterprise sales motion and regional subsidiaries.
The business model combines hardware sales of medical devices and pharmaceutical products with recurring revenue from HomeCare and dialysis services, professional services revenue from the Aesculap Academy training platform and Pharma & MedTech Partner contract development, and OEM/contract manufacturing. Pricing is quote-based and not publicly disclosed, with sales executed primarily through a direct field sales force targeting hospitals, outpatient surgery centers, clinics, and home healthcare patients. Revenue reached €9.4 billion in FY2025 with currency-adjusted growth of 5.1%, distributed across a diversified portfolio that competes with BD, Baxter, ICU Medical, Fresenius Kabi, Boston Scientific, and others across multiple medtech segments. The company maintains global manufacturing and regulatory infrastructure (EU MDR, FDA, Australian TGA) and pursues inorganic growth through targeted acquisitions such as True Digital Surgery (September 2025) while divesting non-core assets such as the endoscopic vacuum therapy line sold to Boston Scientific in March 2024.
B. Braun SE firmographics
Firmographics- Name
- B. Braun SE
- Legal name
- B. Braun SE
- Website
- https://bbraun.de
- Company type
- Private
- Founded year
- 1839
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- B. Braun SE is a privately held German medical technology and pharmaceutical company that manufactures infusion therapy systems, surgical instruments, dialysis products, and clinical nutrition solutions for hospitals and home healthcare patients across more than 40 countries. Revenue reached €9.4 billion in FY2025.
- Ownership category
- akta.pro rank
B. Braun SE industry classification
Industry- Product category
- Medical Devices and Pharmaceutical Products
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Pharmaceutical Preparation Manufacturing (325412), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834), Electromedical & Electrotherapeutic Apparatus (3845), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
- akta.pro primary industry
- Surgical Stapling, Suturing & Hemostasis (Staplers, Clips, Sealants, Tourniquets) (HLAHADAL)
- akta.pro secondary industries
- Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN), Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests) (CRADAMAK)
Keywords
Where B. Braun SE is headquartered
LocationHeadquarters
- HQ city
- Melsungen
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
B. Braun SE business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Medical Devices and Equipment Sales: Sale of medical devices including infusion systems, surgical instruments, catheters, dialysis equipment, and other medical technology products to healthcare facilities globally
- Pharmaceutical Products: Pharmaceutical products including clinical nutrition, infusion solutions, and medication delivery systems
- OEM/Contract Manufacturing Services: Rebranded as B. Braun Pharma & MedTech Partner, providing early-stage development support, regulatory navigation, manufacturing, packaging, and lifecycle management services for pharmaceutical and medtech customers
- HomeCare Services: Coordinating medical care for patients discharged from hospital, including dialysis services, infusion therapy, and chronic disease management at home
- Aesculap Academy Training: Medical education and training services for healthcare professionals
Go-to-market motion1 record
Distribution channels5 records
Marketing channels7 records
B. Braun SE product offering
Product offeringCore offering
B. Braun SE manufactures and sells medical devices, surgical instruments, and pharmaceutical products across more than 15 therapy areas including infusion therapy, surgical instruments, clinical nutrition, extracorporeal blood treatment (dialysis), hygiene management, interventional vascular therapy, minimally invasive surgery, wound management, orthopedic joint replacement, pain therapy, continence care and urology, neurosurgery, and spinal surgery. The company complements its product portfolio with HomeCare services, Aesculap Academy medical training, and the rebranded Pharma & MedTech Partner contract manufacturing business for pharmaceutical and medtech companies.
Product overview
B. Braun SE is a global medical technology company offering a comprehensive portfolio of healthcare products and solutions organized around integrated care pathways. The company's offerings span infusion therapy (Spaceplus automated infusion systems with OnlineSuite digital management), surgical solutions (Aesculap instruments, EinsteinVision 3D fluorescence imaging, robotic surgery), clinical nutrition therapy, extracorporeal blood treatment (dialysis), continence care and urology, wound management, and hospital IT integration. B. Braun positions itself as a full-solution provider through its Aesculap Academy training services, HomeCare patient services, and its rebranded Pharma & MedTech Partner OEM division, enabling the company to serve healthcare facilities from consumables to capital equipment across the entire care continuum.
Differentiator
Problem solved
Functional benefit
Brands
- AESCULAP EinsteinVision 3.0 FI: 3D fluorescence imaging system for surgical visualization
- Spaceplus
- Agile OP-Versorgung
- Aesculap Academy
- B. Braun HomeCare
- B. Braun OEM Division
- My B. Braun
Products and services
- Spaceplus Automated Infusion System
Quantifiable outcome
- Revenue of €9.4 billion in FY 2025 with 5.1% currency-adjusted growth
- +2 more outcomes
Companies that use B. Braun SE
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
B. Braun SE technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature5 records
B. Braun SE partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered minor and core.
- Butterfly NetworkminorCaroll H. Neubauer, former Chairman and CEO of B. Braun USA with 29 years of B. Braun experience (grew revenue from $1B to $8B+), appointed to Butterfly Network's Board of Directors. Brings healthcare executive expertise to Butterfly's semiconductor-based ultrasound platform, cloud software, and AI offerings.
- Royal Philips N.V.corePhilips collaborates with B. Braun to integrate their ventilators, anesthesia machines, and infusion pumps into Philips' patient monitoring ecosystem using Service-oriented Device Connectivity (SDC) standards. Part of Philips' Open operating room concept to consolidate patient monitoring and streamline clinical workflows from OR to ICU.
- Bookdialysis.comcoreStrategic collaboration under which B. Braun's dialysis centers join the curated global bookdialysis network. Partnership aims to expand access to safe, high-quality, and reliable renal care for chronic kidney disease patients who wish to travel, combining B. Braun's clinical standards with bookdialysis's travel coordination expertise.
- GIZ (Deutsche Gesellschaft für Internationale Zusammenarbeit)minorB. Braun joined GIZ and other medical technology companies (Delft Imaging, Drager, Sysmex Europe, Area9 Lyceum) to retrofit biomedical engineering laboratories at Kwame Nkrumah University of Science and Technology and University of Ghana. Project funded through develoPPP programme to provide industry-ready training for biomedical engineering students.
- True Digital SurgerycoreB. Braun acquired True Digital Surgery in September 2025 to enhance its digital surgery technology capabilities. This strategic acquisition strengthens B. Braun's position in surgical visualization and navigation technologies.
- Royal Philips N.V.corePhilips collaborated with B. Braun Melsungen AG alongside Dräger, Hamilton Medical, Getinge, and Lowenstein to introduce an open patient monitoring ecosystem designed for vendor-neutral device connectivity in July 2025.
- Boston Scientific CorporationminorBoston Scientific acquired endoscopic vacuum therapy assets from B. Braun Group in March 2024 to strengthen its portfolio in minimally invasive treatments. B. Braun divested this asset category to Boston Scientific.
Scale indicators10 records
Recent moves7 records
Expansion highlights6 records
B. Braun SE competitors and assessment
Company assessmentBroad incumbents
- Medtronic plc: Medtronic is a diversified medical device leader with overlapping portfolios in surgical instruments, neurosurgery, infusion pumps, and patient monitoring. Both companies serve the same hospital systems across multiple therapy areas.
- Stryker Corporation: Stryker is a broader medical device incumbent with overlapping exposure to surgical instruments, orthopedic joint replacement, and operating room equipment. While Stryker is more focused on orthopedics, both companies compete in surgical and orthopedic procedure markets.
- Boston Scientific Corporation: Boston Scientific acquired endoscopic vacuum therapy assets from B. Braun in March 2024 and competes in interventional vascular therapy and minimally invasive surgery. The recent acquisition illustrates Boston Scientific's strategy of acquiring B. Braun-adjacent assets.
- Johnson & Johnson (MedTech / Ethicon): Johnson & Johnson's MedTech division (Ethicon, DePuy Synthes) competes with B. Braun in surgical instruments, suturing, wound management, and orthopedic joint replacement. J&J is a much larger diversified medtech incumbent.
- Smith+Nephew: Smith+Nephew is a diversified medtech player with overlapping exposure to wound management, orthopedics, and sports medicine, competing with B. Braun in advanced wound care and orthopedic joint replacement.
Direct peers
- Baxter International: Baxter is a direct competitor across IV infusion therapy, IV solutions, pumps, and surgical products. Both companies sell infusion sets, catheters, and clinical nutrition products into overlapping hospital customers.
- Fresenius SE & Co. KGaA: Fresenius Kabi, a Fresenius SE subsidiary, is a direct competitor in IV infusion therapy, clinical nutrition, and IV fluids. Fresenius also operates Fresenius Medical Care for dialysis services, making it B. Braun's closest multi-vertical competitor in infusion and renal care.
- Becton, Dickinson and Company (BD): BD is a direct competitor in IV equipment, infusion therapy, and medication delivery systems. Both companies are identified as major players in IV equipment alongside ICU Medical in the same market.
- ICU Medical: ICU Medical competes directly with B. Braun in IV infusion equipment and Y-shaped infusion line connectors. Both serve the same hospital customer base with comparable infusion therapy product portfolios.
Emerging players
- ConvaTec Group: ConvaTec focuses on wound management, continence care, ostomy care, and infusion sets, partially overlapping with B. Braun's wound management, continence care/urology, and infusion therapy categories.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
B. Braun SE compliance and trust
Trust signalCompliance2 records
B. Braun SE financial estimates
Financial estimateRevenue estimate
Valuation estimate
B. Braun SE leadership team
Management profileNumber of profiles
Profiles8 records
B. Braun SE subsidiaries and ownership
Company hierarchySubsidiaries8 records
B. Braun SE funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
B. Braun SE M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about B. Braun SE
What does B. Braun SE do?
B. Braun SE manufactures and sells medical devices, surgical instruments, and pharmaceutical products across more than 15 therapy areas including infusion therapy, surgical instruments, clinical nutrition, extracorporeal blood treatment (dialysis), hygiene management, interventional vascular therapy, minimally invasive surgery, wound management, orthopedic joint replacement, pain therapy, continence care and urology, neurosurgery, and spinal surgery. The company complements its product portfolio with HomeCare services, Aesculap Academy medical training, and the rebranded Pharma & MedTech Partner contract manufacturing business for pharmaceutical and medtech companies.
Is B. Braun SE a public or private company?
B. Braun SE is a private company. It is classified as family owned and is currently operating.
When was B. Braun SE founded?
B. Braun SE was founded in 1839. It employs 5,001 to 10,000 people.
Where is B. Braun SE based?
B. Braun SE is headquartered in Melsungen, Germany, in the Europe region.
How does B. Braun SE make money?
Five revenue lines are on record. Medical Devices and Equipment Sales are the primary driver. The others are pharmaceutical Products, OEM/Contract Manufacturing Services, homeCare Services and aesculap Academy Training.
Who are B. Braun SE's main competitors?
Broad incumbents on record are Medtronic plc, Stryker Corporation, Boston Scientific Corporation, Johnson & Johnson (MedTech / Ethicon) and Smith+Nephew. Direct peers are Baxter International, Fresenius SE & Co. KGaA, Becton, Dickinson and Company (BD) and ICU Medical. ConvaTec Group is listed as an emerging player.
Does B. Braun SE have an API?
No public API is recorded for B. Braun SE.
What industry is B. Braun SE in?
B. Braun SE's product category is Medical Devices and Pharmaceutical Products. Its primary akta.pro industry code is HLAHADAL, Surgical Stapling, Suturing & Hemostasis (Staplers, Clips, Sealants, Tourniquets), with a secondary code of HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals. Its NAICS code is 339112 and its SIC code is 3841.